NCT00092456已完成3 期
Comparison of the Immunogenicity and Safety of Three Consistency Lots of V260 in Healthy Infants
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 793
- 主要终点
- Serum Neutralizing Antibodies (SNA) Response Against Rotavirus Serotypes G1, G2, G3, G4 and P1A[8]
研究概览
简要总结
This study was designed to evaluate consistency in the antibody response to three manufactured lots of an investigational Rotavirus Vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 6 Weeks 至 12 Weeks（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy infants
排除标准
- •History of abdominal disorders from a birth defect, intussusception, or abdominal surgery
- •Known or suspected problems with the immune system
- •Fever at time of immunization
- •Prior administration of a rotavirus vaccine
- •History of known prior rotavirus disease, chronic diarrhea, or failure to thrive.
结局指标
主要结局
Serum Neutralizing Antibodies (SNA) Response Against Rotavirus Serotypes G1, G2, G3, G4 and P1A[8]
时间窗: 42 days following the 3rd vaccination
Antibody response to 3 manufactured lots of RotaTeq™ and placebo groups, based on the SNA PostDose 3 geometric mean titers (GMTs) (expressed in dilution units) against rotavirus serotypes G1, G2, G3, G4 and P1A\[8\]
次要结局
未报告次要终点
研究者
相似试验
已完成
4 期
Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B VaccineHepatitis AHepatitis BNCT02445703Sinovac Biotech Co., Ltd301
已完成
4 期
Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese InfantsPolioNCT03147560Zhejiang Provincial Center for Disease Control and Prevention528
招募中
3 期
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of AgeChickenpoxNCT06740630GlaxoSmithKline1,840
已完成
3 期
Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-BHepatitis BNCT00698087GlaxoSmithKline60
已完成
2 期
Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 yHepatitis BNCT00698555GlaxoSmithKline163